HER2 Amplification Shows Prognostic Capabilities in mCRC

HER2 amplification appears to be prognostic in patients with RAS wild-type metastatic colorectal cancer but may not be predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.

Related Keywords

,Panitumumab Vs Bevacizumab ,Patients With Ras Wild Type Metastatic Colorectal Cancer ,Paradigm Trial ,Nct02394795 ,